ORMDL3 and hepatocellular carcinoma: In summary, it is shown that sorafenib can inhibit the growth of hepatoma in mice, and silencing the expression of ORMDL3 in liver cancer cells can increase the inhibitory effect of sorafenib on the growth of hepatoma in mice.